Confirmation of I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders.

Publication date: Mar 20, 2020

Rationale: To conduct a retrospective study comparing three I-FP-CIT-SPECT quantitative methods in patients with neurodegenerative syndromes as referenced to neuropathological findings. Methods:I-FP-CIT-SPECT and neuropathological findings among patients with neurodegenerative syndromes from the Mayo Alzheimer’s Disease Research Center and Mayo Clinic Study of Aging were examined. Three I-FP-CIT-SPECT quantitative assessment Methods: MIMneuro (MIM Software Inc.), DaTQUANT (GE Healthcare), and manual region of interest (ROI) creation on an Advantage Workstation (GE Healthcare) were compared to neuropathological findings describing the presence or absence of Lewy body disease (LBD). Striatum to background ratios (SBRs) generated by DaTQUANT were compared to the calculated SBRs of the manual method and MIMneuro. The left and right SBRs for caudate, putamen and striatum were evaluated with the manual method. For DaTQUANT and MIMneuro the left, right, total and average SBRs and z-scores for whole striatum, caudate, putamen, anterior putamen, and posterior putamen were calculated. Results: The cohort included 24 patients [20 (83%) male, aged 75.4 +/- 10.0 at death]. The antemortem clinical diagnoses were Alzheimer’s disease dementia (ADem, N = 6), probable dementia with Lewy bodies (pDLB, N = 12), mixed ADem/pDLB (N = 1), Parkinson’s disease with mild cognitive impairment (N = 2), corticobasal syndrome (N = 1), idiopathic rapid eye movement sleep behavior disorder (iRBD) (N = 1) and behavioral variant frontotemporal dementia (N = 1). Seventeen (71%) had LBD pathology. All three I-FP-CIT-SPECT quantitative methods had area under the receiver operating characteristics (AUROC) values above 0.93 and up to 1.000 (p

Maltais, D.D., Jordan, L.G., Min, H.K., Miyawaga, T., Pryzbleski, S., Lesnick, T.G., Reichard, R.R., Dickson, D.W., Murray, M.E., Kantarci, K., Boeve, B.F., and , Lowe. Confirmation of I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders. 24438. 2020 J Nucl Med.

Concepts Keywords
Alzheimer Dementia
Caudate Putamen Basal ganglia
CIT Psychiatric diagnosis
Cohort Cognitive disorders
Confirmation Neuroscience
Dementia Branches of biology
Frontotemporal Dementia Brain
GE Healthcare Corticobasal syndrome
Healthcare Compared Mild cognitive impairment
Idiopathic RTT
Lewy Bodies Putamen
Mayo Lewy body
Mayo Clinic
Mild Cognitive Impairment
Neurodegenerative Disorders


Type Source Name
drug DRUGBANK L-Citrulline
disease MESH dementia
disease MESH neurodegenerative disorders
disease MESH syndromes
disease MESH Aging
disease MESH Lewy body disease
disease MESH death
disease MESH diagnoses
disease MESH mild cognitive impairment
disease MESH rapid eye movement sleep behavior disorder
disease MESH frontotemporal dementia
disease MESH pathology
drug DRUGBANK Ioflupane I-123

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *